<DOC>
	<DOCNO>NCT00391248</DOCNO>
	<brief_summary>To improve clinical outcome patient non-small cell lung cancer treat radiation therapy .</brief_summary>
	<brief_title>Phase II Trial Erlotinib Concurrent Palliative Thoracic Radiation Therapy Non-small Cell Lung Cancer ( PEARL )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histologically confirm nonsmall cell lung cancer ( squamous cell , adenocarcinoma , poorly differentiate nonsmall cell carcinoma , combination ) ; Symptomatic patient ( define discretion investigator ) palliative thoracic radiation plan ( 3000cGy/10 fraction ) ; At least 18 year age . Previous erlotinib therapy ; Planned concurrent chemotherapy ; Expected survival le 3 month ; ECOG Performance Status 3 4 ; Multiple CNS metastasis single CNS lesion demonstrate radiologic stability ( screen CT/MRI head require ) ; Granulocyte count &lt; 1,500/mm3 , platelet count &lt; 100,000/mm3 , haemoglobin &lt; 9.0g/dl ; SGOT ( AST ) SGPT ( ALT ) &gt; 2.5 time ( x ) upper limit normal ( ULN ) absence know liver metastasis &gt; 5 x ULN case know liver metastasis ; Alkaline phosphatase ( ALP ) &gt; 2.5 x ULN ; Serum bilirubin &gt; 1.5 ULN ; Serum creatinine &gt; 1.5 ULN creatinine clearance &lt; 60 ml/min ; Serum calcium beyond ULN ; Patients require systemic antifungal therapy , clarithromycin , phenytoin , oral anticoagulation therapy ( see Appendix VI complete list medication ) ; A history interstitial lung disease ; Known sensitivity erlotinib ; Pregnancy , lactation , parturition within previous 30 day ; Unwillingness inability complete require assessment trial ; Mental incompetence , include psychiatric addictive disorder would preclude meaningful informed consent ; History recurrent conjunctivitis keratitis inflammatory change surface eye . Geographically inaccessible treatment followup evaluation ; Involved ongoing therapeutic trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>palliative radiation</keyword>
	<keyword>tarceva</keyword>
	<keyword>palliative thoracic radiation therapy</keyword>
</DOC>